Resmetrix Medical

Wearable Respiratory Monitoring System

Clinical Need

Deterioration in respiratory condition of Corona-virus (COVID-19), Asthma, COPD and Pneumonia patients is detected too late, leading to complications and death.

Hundreds of thousands of people are now infected with Corona virus and require tight monitoring of their clinical condition from a distance, especially their lung function, both at home or isolated area and at the hospital. Many mild patients are deteriorating fast, reaching severe pneumonia and require mechanical ventilation and are at high risk of death. Late detection of this deterioration can be lethal.

Moderate Corona patients - at risk of late detection of further respiratory deterioration within the hospital. 
Recovered Corona patients - can be discharged early to quarantine environment.

Late detection of life threatening attacks in home environment.
In COPD, 20% of hospitalized patients get readmitted within 30 days following their initial hospital discharge.

By the Numbers United States:
  • Asthma - 25 Million Patients; 439K Inpatient Annually; 1.8M ER Visits Annually Total Cost to System: $82B
  • COPD - 16+ Million Patients; 3rd Leading Cause of Death Readmission Rate: 19.2%; Total Cost to System: $32B




Resmetrix has developed a novel wearable respiratory monitoring system, that accurately monitors the respiratory pattern of respiratory disease patients (COVID-19, COPD, Asthma) and alert to the patient smartphone, and the medical team, when early signs of respiratory deterioration occur.

Resmetrix unique wearable sensor (based on novel proprietary sensor built into a chest strap or a patch over the chest), wirelessly connected to a smartphone app, monitors at-risk patients in real-time, 24/7, anywhere, in any setting. Resmetrix system is the only system that detects small changes in a patient’s breathing pattern, tidal volume and other vital signs (Heart Rate, Temperature) and will provide immediate, early warning signs of deterioration in lung function (based on each patient respiratory pattern).

Our tele-monitoring system can monitor Corona patients at home, at quarantine environment or at the Hospital, send alarm to the medical teams when patients are starting to deteriorate, so they can provide treatment early, hence avoiding lung failure and death.  




Clinical Validation

Clinical study at Rambam Medical Center:

  • Resmetrix clinical results show high correlation between respiratory signals from Resmetrix’ strap and a spirometer/flow meter tidal volume signals.
  • In asthmatic patients, the system detected successfully changes in respiratory patterns during mild attack and response to treatment.
  • Studies in exercise, the system demonstrate the ability to continuously and accurately monitor the respiratory signals in various levels of exercise.


About Us

Resmetrix has developed unique portable respiratory monitoring system: A wearable wireless chest strap that monitors, records and analyses continuously and accurately breathing patterns and alerts for early signs of deterioration in a patient’s clinical condition. The system provides a platform of respiratory disease management. 
Resmetrix is a portfolio company of MindUP incubator, a partnership of Medtronic, IBM, Pitango and Rambam Medical Center in Israel. 

Resmetrix won third place in RESI Innovation challenge (Boston, US, Sep. 2019):

The Times of Israel:


Resmetrix started crowdfunding with Together angels club platform:

Resmetrix publication December 2019: